Clinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multicenter Study from the Turkish Oncology Group Kidney Cancer Consortium

Basit Öğe Kaydı
dc.authoridUcar, Gokhan/0000-0002-7649-1075
dc.authoridErturk, Ismail/0000-0001-6835-0988
dc.authoridYekedüz, Emre/0000-0001-6819-5930
dc.authoridEROL, CIHAN/0000-0003-3155-8798
dc.authorwosidUcar, Gokhan/AAA-8198-2021
dc.authorwosidSendur, Mehmet Ali Nahit/H-7555-2014
dc.authorwosidErturk, Ismail/B-4317-2019
dc.authorwosidYekedüz, Emre/ABA-5814-2020
dc.contributor.authorErol, Cihan
dc.contributor.authorYekeduz, Emre
dc.contributor.authorTural, Deniz
dc.contributor.authorKarakaya, Serdar
dc.contributor.authorOztas, Nihan Senturk
dc.contributor.authorUcar, Gokhan
dc.contributor.authorKilickap, Saadettin
dc.date.accessioned2024-06-12T11:13:31Z
dc.date.available2024-06-12T11:13:31Z
dc.date.issued2023
dc.departmentTrakya Üniversitesien_US
dc.description.abstractIntroduction: We aimed to evaluate clinical features, prognostic factors, and treatment preferences in patients with non-clear cell renal cell carcinoma (nccRCC). Methods: Patients with metastatic nccRCC were selected from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) database. Clinical features, prognostic factors, and overall survival (OS) outcomes were investigated. Results: A total of 118 patients diagnosed with nccRCC were included in this study. The median age at diagnosis was 62 years (interquartile range: 56-69). Papillary (57.6%) and chromophobe tumors (12.7%) are common histologic subtypes. Sarcomatoid differentiation was present in 19.5% of all patients. When the patients were categorized according to the International Metastatic RCC Database Consortium (IMDC) risk scores, 66.9% of the patients were found to be in the intermediate or poor risk group. Approximately half of the patients (55.9%) received interferon in the first line. At the median follow-up of 53.2 months (95% confidence interval [CI]: 34.7-71.8), the median OS was 19.3 months (95% CI: 14.1-24.5). In multivariate analysis, lung metastasis (hazard ratio [HR]:2.22, 95% CI: 1.23-3.99) and IMDC risk score (HR: 2.35, 95% CI: 1.01-5.44 for intermediate risk; HR: 8.86, 95% CI: 3.47-22.61 for poor risk) were found to be independent prognostic factors. Conclusion: In this study, survival outcomes are consistent with previous studies. The IMDC risk score and lung metastasis are the independent prognostic factors for OS. This is an area that needs research to better treat this group of patients and create new treatment options.en_US
dc.identifier.doi10.1159/000528994
dc.identifier.endpage601en_US
dc.identifier.issn0042-1138
dc.identifier.issn1423-0399
dc.identifier.issue6en_US
dc.identifier.pmid36996793en_US
dc.identifier.scopus2-s2.0-85152122023en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage595en_US
dc.identifier.urihttps://doi.org/10.1159/000528994
dc.identifier.urihttps://hdl.handle.net/20.500.14551/23583
dc.identifier.volume107en_US
dc.identifier.wosWOS:000963329200001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofUrologia Internationalisen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectRenal Cell Canceren_US
dc.subjectPrognostic Factorsen_US
dc.subjectNon-Clear Cellen_US
dc.subjectKidney Tumoren_US
dc.subjectOpen-Labelen_US
dc.subject1st-Lineen_US
dc.subjectSunitiniben_US
dc.subjectMetaanalysisen_US
dc.subjectEverolimusen_US
dc.subjectPazopaniben_US
dc.titleClinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multicenter Study from the Turkish Oncology Group Kidney Cancer Consortiumen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu